Adaptimmune announces the release of interim results from a pilot clinical trial 04511 of NY-ESOc259T which uses a patient’s own T cells that have been genetically altered to attack synovial sarcoma cells.
Please click on the link below to download the full Press Release:-
Adaptimmune Announces Interim Results from Pilot Trial of its Engineered NY-ESO T Cells...
Adaptimmune has won the Best New Biotech Development Programme Award of 2014 at the OBN annual awards. The prestigious industry award recognizes Adaptimmune’s achievement in securing a strategic collaboration and licensing agreement with GlaxoSmithKline (GSK) for the development and commercialization of its lead clinical cancer programme. Please click on the link below to download the full Press Release:- Adaptimmune wins OBN Best New Biotech Development Programme of 2014 ...
Adaptimmune Limited, a leading biotechnology company focused on the use of T-cell therapy to treat cancer and infectious disease, today announced the completion of a $104 million Series A financing round. Please click on the link below to download the full Press Release:- Adaptimmune secures $104 million in Series A Financing ...
Adaptimmune today announced that it has been named by FierceBiotech as one of 2014’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.
Please click on the link below to download the full Press Release:-
FierceBiotech names Adaptimmune as one of its “Fierce 15” Biotech Companies of 2014...
Adaptimmune Limited, a leading biotechnology company developing TCR engineered T-cells to treat cancer, today announced that it has entered into a strategic collaboration and licensing agreement with GlaxoSmithKline (GSK) for the development and commercialisation of its lead clinical cancer programme.
Please click on the link below to download the full Press Release:-
Adaptimmune enters strategic cancer immunotherapy collaboration with GlaxoSmithKline to develop and commercialise novel cell-ba...
Bent Jakobsen, CSO to Adaptimmune, is presenting at AACR in San Diego on Tuesday 8th April, 3.00pm – 5.00pm in the session entitled: “CIMT-AACR-CIMM Joint Session on Deciphering and modulating T-cell specificity in clinically effective antitumor responses”...
Adaptimmune Limited, the biotechnology company focused on the use of engineered T cells to treat cancer, today announced the full-time appointment of James Noble as Chief Executive Officer. Mr Noble has been CEO of Adaptimmune since its formation in 2008, but until now has been combining this position with his role as CEO of sister company, Immunocore. He will remain on the Board of Immunocore as a non-executive director.
Please click on the link below to download the full Press Release:-
Adap...
Adaptimmune has been awarded a grant of £2.1 million from the Biomedical Catalyst Fund, managed by the UK’s innovation agency the Technology Strategy Board and the Medical Research Council. The prestigious award will expedite the development of Adaptimmune’s second engineered T cell therapy programme into the clinic in triple negative breast cancer.
Please click on the link below to download the full Press Release:-
Adaptimmune announces award of £2.1m from the Biomedical Catalyst Fund...
